Mediar Therapeutics and Eli Lilly Ink Deal for IPF Drug MTX-463
US-based clinical-stage biotech Mediar Therapeutics, Inc. has announced a global license agreement with Eli Lilly...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity